GlaxoSmithKline studies show orlistat plus diet leads to weight loss

By Lisa Kerner

Charlotte, N.C., Sept. 7 - GlaxoSmithKline said results from three clinical studies of its low-dose orlistat (60 mg) combined with a reduced-calorie diet demonstrated weight loss and improved cholesterol and blood pressure levels in 1,729 overweight and obese individuals.

Specifically, orlistat users lost 5% or more of their baseline body weight compared to the diet alone group at six months and 12 months, according to data presented at the 2006 International Conference on Obesity in Sydney, Australia.

Studies also showed that 60 mg orlistat provides better tolerability compared to 120 mg Xenical.

Orlistat, currently under review by the Food and Drug Administration, prevents the absorption of about 25% of the fat consumed.

GlaxoSmithKline, a London-based pharmaceutical company, plans to market orlistat under the brand name Alli following FDA approval.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.